BioCorRx Inc. (BICX)
OTCMKTS · Delayed Price · Currency is USD
0.3052
-0.0948 (-23.70%)
Dec 24, 2025, 12:27 PM EST
BioCorRx Revenue
BioCorRx had revenue of $635.22K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $948.36K, up 3,464.87% year-over-year. In the year 2024, BioCorRx had annual revenue of $7.67K, down -91.40%.
Revenue (ttm)
948.36K
Revenue Growth
+3,464.87%
P/S Ratio
7.82
Revenue / Employee
316.12K
Employees
3
Market Cap
7.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 7.67K | -81.50K | -91.40% |
| Dec 31, 2023 | 89.16K | -124.68K | -58.31% |
| Dec 31, 2022 | 213.84K | 165.57K | 342.99% |
| Dec 31, 2021 | 48.27K | -74.35K | -60.63% |
| Dec 31, 2020 | 122.62K | -117.64K | -48.96% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Northwest Biotherapeutics | 937.00K |
BioCorRx News
- 14 days ago - BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th - GlobeNewsWire
- 5 weeks ago - Diamond Equity Research Releases Update Note on BioCorRx®, Inc. (OTCQB: BICX) - GlobeNewsWire
- 4 months ago - Diamond Equity Research Initiates Coverage on BioCorRx®, Inc. (OTCQB: BICX) - GlobeNewsWire
- 1 year ago - BioCorRx GAAP EPS of -$0.13, revenue of $4.04M - Seeking Alpha
- 1 year ago - BioCorRx Reports Business Update for the Second Quarter of 2024 - GlobeNewsWire
- 1 year ago - BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia - GlobeNewsWire
- 1 year ago - BioCorRx Reports Business Update for 2023 - GlobeNewsWire
- 1 year ago - BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD - GlobeNewsWire